{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostate-cancer/prescribing-information/medroxyprogesterone-acetate/","result":{"pageContext":{"chapter":{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate","depth":2,"htmlHeader":"<!-- begin field 6af2318b-5456-44c7-a849-a7c300a88566 --><h2>Medroxyprogesterone acetate</h2><!-- end field 6af2318b-5456-44c7-a849-a7c300a88566 -->","summary":"","htmlStringContent":"<!-- begin item 58d4bc1c-1659-4de2-9cc7-a7c300a87ee6 --><!-- end item 58d4bc1c-1659-4de2-9cc7-a7c300a87ee6 -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","lastRevised":"Last revised in October 2017","chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","fullItemName":"Management","slug":"management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0af84a76-2122-5cfb-83e5-ab086cce8eca","slug":"indications","fullItemName":"Indications","depth":3,"htmlHeader":"<!-- begin field 11cf532a-b98b-4b9f-bf39-a7c300a9c0e6 --><h3>Indications</h3><!-- end field 11cf532a-b98b-4b9f-bf39-a7c300a9c0e6 -->","summary":"","htmlStringContent":"<!-- begin item b8307da1-0d0d-478b-b45a-a7c300a9be9c --><!-- begin field cda0c642-05e9-4a9a-b14b-a7c300a9c0e6 --><ul><li>Management of hot flushes caused by long-term androgen suppression in men with prostate cancer. <ul><li>This indication is outwith the product licence.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BNF 73, 2017</a>]</p><!-- end field cda0c642-05e9-4a9a-b14b-a7c300a9c0e6 --><!-- end item b8307da1-0d0d-478b-b45a-a7c300a9be9c -->","subChapters":[]},{"id":"4a732c50-cf3e-50fb-bd12-2212d1657f66","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field b5139f31-00c6-47d2-bc3a-a7c300a9fa0c --><h3>Dose</h3><!-- end field b5139f31-00c6-47d2-bc3a-a7c300a9fa0c -->","summary":"","htmlStringContent":"<!-- begin item 3c1246e5-1658-4061-98de-a7c300a9f858 --><!-- begin field de6de117-2fe2-4587-9a7a-a7c300a9fa0c --><ul><li>For the treatment of hot flushes caused by long-term androgen suppression in men. <ul><li>20 mg daily, initially for a period of 10 weeks.</li><li>Treatment should be evaluated at the end of this period.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>]</p><!-- end field de6de117-2fe2-4587-9a7a-a7c300a9fa0c --><!-- end item 3c1246e5-1658-4061-98de-a7c300a9f858 -->","subChapters":[]},{"id":"6df2c1b4-bd78-5cf1-bf66-6258f68e75ca","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7c3c1a36-e46c-421b-9aca-a7c300aa927c --><h3>Contraindications and cautions</h3><!-- end field 7c3c1a36-e46c-421b-9aca-a7c300aa927c -->","summary":"","htmlStringContent":"<!-- begin item ec163186-ad83-49c8-b9bc-a7c300aa909f --><!-- begin field 5e909f9e-468c-41a0-bb4b-a7c300aa927c --><ul><li><strong>Do not prescribe medroxyprogesterone acetate to:</strong><ul><li>Acute liver disease, or a history of liver disease.</li><li>Previous idiopathic, or current venous thromboembolism.</li><li>Active or recent arterial thromboembolic disease (for example, angina, myocardial infarction).</li><li>Porphyria.</li></ul></li><li><strong>Prescribe medroxyprogesterone acetate with caution to men with:</strong><ul><li>Asthma.</li><li>Cardiac dysfunction.</li><li>Conditions that may worsen with fluid retention.</li><li>Diabetes (progestogens can decrease glucose tolerance—monitor patient closely).</li><li>Epilepsy.</li><li>History of depression. </li><li>Hypertension.</li><li>Migraine.</li><li>Susceptibility to thromboembolism.</li><li>Systemic lupus erythematosus.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BNF 73, 2017</a>]</p><!-- end field 5e909f9e-468c-41a0-bb4b-a7c300aa927c --><!-- end item ec163186-ad83-49c8-b9bc-a7c300aa909f -->","subChapters":[]},{"id":"94e25843-3b10-562a-b580-cd70a7b42e10","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7d74ca19-2dec-4a95-9dd6-a7c300aaecda --><h3>Adverse effects</h3><!-- end field 7d74ca19-2dec-4a95-9dd6-a7c300aaecda -->","summary":"","htmlStringContent":"<!-- begin item 10e879ba-9f23-4fce-9207-a7c300aaeb34 --><!-- begin field 2c448d55-8e63-478e-84a6-a7c300aaecda --><ul><li><strong>Possible adverse effects of medroxyprogesterone acetate include:</strong><ul><li>Psychiatric — depression, insomnia, nervousness (common).</li><li>Nervous system — headache (very common), dizziness (common).</li><li>Gastrointestinal — nausea (very common), indigestion (frequency unknown) vomiting (frequency unknown).</li></ul></li><li>Other possible adverse effects include changes in libido, loss of vision and weight gain.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BNF 73, 2017</a>]</p><!-- end field 2c448d55-8e63-478e-84a6-a7c300aaecda --><!-- end item 10e879ba-9f23-4fce-9207-a7c300aaeb34 -->","subChapters":[]},{"id":"a37fb889-8e4c-5090-8e06-a25b126e0920","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f15c57ce-2b0f-49aa-a17f-a7c300ab1cdd --><h3>Drug interactions</h3><!-- end field f15c57ce-2b0f-49aa-a17f-a7c300ab1cdd -->","summary":"","htmlStringContent":"<!-- begin item 05c4c2e8-fb2e-426b-acdd-a7c300ab1a3f --><!-- begin field c706feb8-8ed2-4655-9ab1-a7c300ab1cdd --><ul><li><strong>Possible drug interactions may occur with liver enzyme-inducing drugs, reducing the effect of medroxyprogesterone acetate: </strong><ul><li>Antibiotics — rifampicin and rifabutin are very potent liver enzyme inducers.</li><li>Antiepileptics — carbamazepine, oxcarbazepine, phenytoin, barbiturates, primidone, and topiramate.</li><li>Antiretrovirals — ritonavir, ritonavir-boosted protease inhibitors, efavirenz, and nevirapine.</li><li>St John's wort.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BNF 73, 2017</a>]</p><!-- end field c706feb8-8ed2-4655-9ab1-a7c300ab1cdd --><!-- end item 05c4c2e8-fb2e-426b-acdd-a7c300ab1a3f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}